AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00596856 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Development and dissemination of priority oral health risk assessment and referral guidelines - PORRT
Description: The RCT will compare passive distribution of guidelines by mail to an in-office intervention consisting of guideline distribution combined with educational outreach providing training in guideline use and patient mediated information provided by the risk and referral assessment tool (PORRT). The three-arm trial will consist of 25 medical practices that have never participated in IMB and 25 practices that are currently participating, both of which will receive the guidelines through the mail, and 25 practices currently participating in IMB that will receive the more intense in-office training intervention.
Study NCT00596856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Development and dissemination of priority oral health risk assessment and referral guidelines - PORRT
Description: The RCT will compare passive distribution of guidelines by mail to an in-office intervention consisting of guideline distribution combined with educational outreach providing training in guideline use and patient mediated information provided by the risk and referral assessment tool (PORRT). The three-arm trial will consist of 25 medical practices that have never participated in IMB and 25 practices that are currently participating, both of which will receive the guidelines through the mail, and 25 practices currently participating in IMB that will receive the more intense in-office training intervention.
Study NCT02883192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Zofran 4 mg.
Study NCT02883192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01397201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching fluticasone propionate HFA MDI
Study NCT01397201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching fluticasone propionate HFA MDI
Study NCT01397201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: BI 54903
Study NCT01948401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: additional 0.5 mg/kg orally for 7 days
Study NCT01463709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseCure pulse generator and Derm-pulse electrode
Description: PulseCure 100 ns pulse generator: generates 30 kV/cm electric pulses 100 ns long to trigger apoptosis in cells between the electrodes.~NanoBlate: Delivery device to treat 5 mm wide skin lesions with 100 ns pulses from PulseCure
Study NCT04427033 — intervention group
Intervention type: DEVICE
Intervention: Bone Conduction Implant
Description: Bonebridge system BCI 602
Study NCT01007409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Period 1: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast Period 2: administration of fimasartan 240mg at 9:00am, without the breakfast
Study NCT01007409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Period 1: administration of fimasartan 240mg at 9:00am, without the breakfast Period 2: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast
Study NCT05333653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continouse supportive care
Description: Participants were provided care in different rooms, blinded to the differences in practice used between the two groups. In the same clinic, a room was designed as a positive delivery room by the researchers and a relaxing environment was created. In this room, supportive care parameters recommended by The Royal College of Midwives (2012) were applied to the women in the ICSC group in line with their preferences.~Participants in the control group, on the other hand, received routine care given in the hospital by other midwives in the clinic.
Study NCT05333653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine care
Description: Participants in the control group, on the other hand, received the routine care given in the hospital by other midwives in the clinic, and there was a change of caregiver midwife during shift changes. The care provided in the hospital during delivery is mostly focused on low level of physical comfort and high level of follow-up.
Study NCT02682134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xylocaine
Description: First group were given xylocaine
Study NCT02682134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Second group were given Dexamethasone
Study NCT02682134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine and Dexamethasone
Description: Third group were given both Xylocaine and Dexamethasone
Study NCT04038606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Determination of acceptance and / or rejection of mastectomy
Description: Blood exams,Participants completed a questionnaire translated in French language : Rosenberg,SF-36, QLQC30, Big Five Inventory,BPI-SF.:-)
Study NCT04038606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Determination of acceptance and / or rejection of mastectomy
Description: Blood exams,Participants completed a questionnaire translated in French language : Rosenberg,SF-36, QLQC30, Big Five Inventory,BPI-SF.:-)
Study NCT03737734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Study NCT04269889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag will be administered to participants 12 years of age an above will receive the adult dose of 150 mg by mouth daily. Participants between ages of 6 and 11 years old will start at 75 mg by mouth daily, and children 2 and 5 years of age will start at 2.5 mg/kg, not to exceed 75 mg by mouth daily.~To adjust for the higher expected exposure in participants of East Asian and South East Asian ancestry, the starting dose for East Asian and South East Asian participants 12 years of age and above will be 75 mg by mouth once daily. For East Asian and South East Asian participants between 6 and 11 years of age, the starting dose will be 37.5 mg once daily by mouth, and for children between 2 and 5, the starting dose will be 1.25 mg/kg by mouth.
Study NCT05266261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate Oral Tablet
Description: 150 mg of ibandronate + 24,000 IU of cholecalciferol
Study NCT05266261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate Oral Tablet
Description: 150 mg of ibandronate + 24,000 IU of cholecalciferol
Study NCT02887651 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cavity boost radiation
Description: Cavity boost radiation therapy with 10 x 3 Gy for patients suffering from complete resected cerebral metastases
Study NCT01149135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue enriched light with a low intensity
Description: 30 minutes in the morning, 750 lux
Study NCT01149135 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard light treatment
Description: standard light treatment, 30 minutes, 10 000 lux
Study NCT02783950 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Decipher Prostate Cancer Classifier
Description: The Decipher test (GenomeDx Biosciences, San Diego, CA) is a genomic test that predicts high grade disease, the probability of metastasis and prostate cancer-specific mortality for men with prostate cancer.
Study NCT02939183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Release (IR) Formulation
Description: Immediate Release (IR) Formulation
Study NCT02939183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastro-Retentive (GR) Formulation
Description: Gastro-Retentive (GR) Formulation
Study NCT02939183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone
Study NCT02939183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide
Study NCT01397201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate
Study NCT04691401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence System (CAD EYE, Fujifilm Co.)
Description: A dedicated CNN-based AI system (CAD EYE, Fujifilm Co, Tokyo, Japan) has been recently developed. The Computer-aided diagnosis (CAD) CAD EYE system is a real-time computer-assisted image analysis that allows automatic polyp identification without modifications to the colonoscope or to the actual endoscopic procedure. When CAD EYE identifies a polyp, both a visual (a green blinking box surrounding the identified polyp, called the detection box) and an acoustic alarm pop up and attract the endoscopist attention. Around the endoscopic image a visual assist circle is shown and lights up in the direction where the suspicious polyp is detected.
Study NCT04908657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 20 MG
Description: oral sildenafil 20 mg three times per day for 3 years
Study NCT02583373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAL02 Low-dose
Description: Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion
Study NCT02583373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAL02 High-dose
Description: Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion
Study NCT02583373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered administered 2 times (24 hours apart) as i.v. infusion
Study NCT00792077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5 mg daily for 56 days.
Study NCT03838965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biobeat sensor
Description: biobeat sensor is a noninvasive sensor of the the hymodynamic measures during the childbirth and after 24 hours.
Study NCT00122278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10mg IV
Study NCT02783326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Pulmonary rehabilitation, exercise in COPD individuals and health individuals
Study NCT02783326 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Pulmonary rehabilitation, exercise in COPD individuals and health individuals
Study NCT02260258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Neuromuscular Blockade
Study NCT02260258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline
Study NCT02725411 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Orally administered Celecoxib 100 mg twice daily for 56 weeks
Study NCT02725411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Description: Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
Study NCT02725411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg
Description: Subcutaneous injection of tanezumab 10 mg every 8 weeks for 56 weeks
Study NCT02725411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for celecoxib
Description: Orally administered the placebo twice daily for 56 weeks
Study NCT00122278 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Dexamethasone 10mg IV
Study NCT02002611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobeglitazone
Study NCT02002611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Study NCT05932784 — intervention group
Intervention type: DEVICE
Intervention: transesophageal echocardiography
Description: Utilizing transesophageal echocardiography (TEE) during resuscitation allows medical professionals to determine if a patient's aortic valve is being compressed while receiving chest compressions, providing valuable insight to optimize the resuscitation process.
Study NCT03858478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy arm
Description: BIKTARVY : one tablet QD, every day between D0 and M12 includind - TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg)
Study NCT00315159 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Sentinel Node Biopsy
Description: Inguinal sentinel node biopsy will be performed.
Study NCT01128751 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embol-X intra-aortic emboli filter
Description: Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
Study NCT01128751 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DBT dynamic bubble trap
Description: Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
Study NCT01128751 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Control group
Description: In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
Study NCT04620395 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Punch biopsy
Description: A standardized biopsy kit is used for a synovial fluid tap and subsequent acquisition of up to 7 Punch biopsies through an introducer (part of the kit)
Study NCT01039974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040
Description: GSK962040. Planned doses per cohort as follows:~Cohort 1 planned dose = 10 mg; Cohort 2 to be determined based on data from Cohort 1
Study NCT01039974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 400 mg
Study NCT01050127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-436
Description: See Arm Description for details.
Study NCT01050127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Description for details.
Study NCT04396496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Injection
Description: DARA is a human monoclonal antibody that specifically recognizes the CD38 molecule that is expressed at a high level in a variety of hematological malignancies, including myeloma cells.~DARA injection will be given with oral lenalidomide for up to 12 four week cycles.
Study NCT01297998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine , cisplatin
Description: Dose of gemcitabine and cisplatin and treatment schedule
Study NCT02493582 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-Induced Killer Cells
Description: CIKs are used with Apatinib to treat lung adenocarcinoma patients with wild-type EGFR
Study NCT02493582 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Apatinib
Description: Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.
Study NCT02493582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.
Study NCT00752024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YL-1 type of intracranial hematoma puncture needle
Description: YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.
Study NCT00752024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dehydrating agent, haemostatic
Description: In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
Study NCT02616419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy® device
Description: Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
Study NCT02616419 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maxilene® (Lidocaine liposomal 4%)
Description: Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
Study NCT03589014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Patients randomized to the experimental arm will receive propranolol on top of standard recommended treatment for CCM. Initial oral dose of 40 mg bid will be uptitrated to 80 mg bid in the absence of excessive bradycardia or hypotension. Doses as low as 10 mg bid and up to 160 mg bid, 20 to 320mg daily, are acceptable according to tolerability.
Study NCT00356733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin administration
Description: 50 IU/kg/week EPO to a target haemoglobin level of 13.7 g/dL for men and 13.4 g/dL for women (group A) or to a target comparable to starting hemoglobin level (group B)
Study NCT03718871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV testing at traditional healer practices
Description: HIV 1/2 antigen-antibody POC test (Oraquick©) will be administered to those participants who agree to test. Pre-test counseling will be performed before results are delivered. Clients with positive tests will be provided with detailed contact information for the MUST ISS clinic, and given specific instructions to present to the clinic as soon as possible for confirmatory testing and linkage to care.
Study NCT03298776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Scan
Description: I-Scan is a digital enhancement technique. These endoscopes already have greater definition compared to many standard endoscopes but they also utilise a 'zoom' function and digital image enhancement.
Study NCT03298776 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard endoscopy
Description: Patients referred for standard endoscopy to receive standard of care only
Study NCT01670318 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: platinum chromium everolimus-eluting stent (PROMUS Element by Boston Scientific, Massachusetts)
Study NCT04163497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICU Diaries
Description: To explore the effects of providing an ICU Diary in the symptoms of anxiety, depression and PTSD within patients who were hospitalized in the unit.
Study NCT04036734 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Longitudinal
Description: Longitudinal orientation of ultrasound to long axis of vein to guide access needle
Study NCT04036734 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transverse
Description: Transverse orientation of ultrasound to long axis of vein to guide access needle
Study NCT01193660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Infusion
Description: The subjects will be undertaken allogeneic umbilical cord blood infusion (total nucleated cells > 3x10\^7/kg) intravenously under non-myeloablative immunosuppression (maintaining blood level of cyclosporine as 100-200ng/mL for 1 month).
Study NCT01193660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin Injection
Description: Erythropoietin will be given as the schedule of twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times.
Study NCT01193660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin Injection
Description: Erythropoietin will be given as the schedule of twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times.
Study NCT01193660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Rehabilitation
Description: All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.
Study NCT01193660 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Active Rehabilitation
Description: All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.
Study NCT01193660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Rehabilitation
Description: All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.